Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.

ABSTRACT:

Background

Significant intertumoral heterogeneity exists as antitumor treatment is introduced. Heterogeneous therapeutic responses are conventionally evaluated by imaging examinations based on Response Evaluation Criteria in Solid Tumors (RECIST); nevertheless, there are increasing recognitions that they do not fully capture patient clinical benefits. Currently, there is a paucity of data regarding the clinical implication of biological responses assessed by liquid biopsy of on-treatment circulating tumor DNA (ctDNA). Here, we investigated whether biological response evaluated by ctDNA kinetics added critical information to the RECIST, and whether integrating on-treatment biological response information refined risk stratification of cancer patients.

Methods

In this populati

SUBMITTER: Lv J 

PROVIDER: S-EPMC9396864 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature